Clinical Trials for Ovarian Cancer

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors (ECOG 0-1, no active CNS metastases) to receive GI-102, a bispecific CD80–IL-2 variant fusion protein designed to selectively activate CD8+ T and NK cells, as monotherapy or combined with standard regimens, including pembrolizumab and trastuzumab deruxtecan (for HER2+ disease).

ClinicalTrials.gov ID: NCT05824975

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with advanced, HER2-expressing solid tumors (including gynecologic, urothelial, biliary tract, breast, lung, and gastrointestinal cancers) who have progressed after at least two prior lines of standard therapy. All participants receive BL-M07D1, an investigational HER2-directed antibody-drug conjugate that delivers a topoisomerase I inhibitor (Ed-04) selectively to tumor cells via IV infusion every 21 days.

ClinicalTrials.gov ID: NCT06293898

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors (excluding primary CNS tumors); for IDE161 monotherapy, patients must have BRCA1/2 or other homologous recombination deficiency gene alterations, while the combination arm is for patients with advanced or recurrent endometrial cancer who have progressed on prior anti–PD-1/L1 therapy. IDE161 is an investigational oral inhibitor of poly(ADP-ribose) glycohydrolase (PARG), targeting DNA repair in HR-deficient tumors, given alone or in combination with pembrolizumab.

ClinicalTrials.gov ID: NCT05787587

A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with select advanced/metastatic solid tumors after standard therapy (melanoma, cSCC, Merkel cell, NSCLC, HNSCC, gastric/GEJ, RCC, HGSOC, TNBC) receive AZD6750, an investigational CD8-guided IL-2 designed to preferentially activate CD8+ T cells; a separate module enrolls NSCLC (including 1L PD-L1 ≥1%) to receive AZD6750 plus rilvegostomig, a bispecific PD-1/TIGIT antibody. Key exclusions include uncontrolled CNS disease, active autoimmune disease, prior severe I/O toxicities, and in the NSCLC module prior anti-TIGIT or targetable driver-positive 1L disease.

ClinicalTrials.gov ID: NCT07115043

A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent epithelial ovarian/fallopian tube/primary peritoneal or endometrial cancers after ≥1 platinum regimen (ovarian must be platinum‑resistant; prior MEK inhibitor required for low‑grade serous; MSI‑H/dMMR endometrial requires prior PD‑1/PD‑L1 or ineligibility) receive weekly IV pelcitoclax (dual BCL‑2/BCL‑xL inhibitor prodrug with preferential BCL‑xL activity) plus oral cobimetinib (MEK inhibitor) on days 1–21 of 28‑day cycles. Key exclusions include prior BCL inhibitor exposure and strong CYP3A4 modulators; treated/stable brain metastases are allowed.

ClinicalTrials.gov ID: NCT05691504

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, measurable solid tumors (ECOG 0–1) eligible for biopsy, including FRα‑expressing cancers such as ovarian, receive the investigational FRα‑targeted topoisomerase‑I ADC AZD5335 (torvutatug samrotecan) as monotherapy or combined with bevacizumab, carboplatin (± bevacizumab), or PARP1‑selective inhibitors (saruparib or AZD9574). Aimed at patients who have exhausted standard options, with exclusions for uncontrolled CNS disease and significant comorbidities; early data suggest higher activity in FRα‑high tumors.

ClinicalTrials.gov ID: NCT05797168

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent clear cell or endometrioid ovarian carcinoma, platinum‑resistant HGSOC (dose‑escalation only), or recurrent FIGO grade 1 endometrioid/clear cell endometrial carcinoma receive oral tuvusertib (ATR inhibitor) plus ZEN‑3694 (pan‑BET inhibitor), with biomarker‑driven expansion enrolling both ARID1A‑mutated and ARID1A‑wild‑type cohorts. Aims include defining RP2D and assessing safety and preliminary activity, with mandated biopsies to explore pharmacodynamic effects and ARID1A‑related response.

ClinicalTrials.gov ID: NCT05950464

A Prospective Randomized Trial of Acute Normovolemic Hemodilution (ANH) in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with suspected or confirmed stage IIIC–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer undergoing primary or interval cytoreductive laparotomy (BLOODS ≥2, Hgb ≥10 g/dL) are randomized to intraoperative acute normovolemic hemodilution (autologous whole-blood collection with crystalloid/colloid replacement and reinfusion) versus standard intraoperative care. The trial tests whether ANH reduces perioperative allogeneic red blood cell transfusion within 30 days.

ClinicalTrials.gov ID: NCT06290193

Phase I Clinical Trial of Autologous B7-H3 Chimeric Receptor (CAR) T Cells in Adults With Recurrent, Platinum Resistant Ovarian Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent, platinum-refractory or -resistant epithelial ovarian cancer (including carcinosarcoma), ECOG 0–2, receive autologous B7‑H3 (CD276)–targeted CAR T cells after lymphodepletion, administered either intraperitoneally for peritoneal-only disease or intravenously if extra-peritoneal or IP not feasible. Investigational therapy targets broadly overexpressed B7‑H3; trial assesses feasibility/safety with dose escalation and early response signals.

ClinicalTrials.gov ID: NCT06646627

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with measurable high-grade serous ovarian, primary peritoneal, or fallopian tube cancer after 1–3 prior lines (platinum-sensitive and -resistant cohorts; ECOG 0–1), excluding significant ILD/pneumonitis and other key comorbidities. Investigational CDH6-targeting antibody-drug conjugate raludotatug deruxtecan (anti-CDH6–DXd topoisomerase I payload) is combined with either carboplatin, paclitaxel, or bevacizumab, with chemotherapy for up to six cycles and continued R-DXd until progression.

ClinicalTrials.gov ID: NCT06843447